Evidence from Clinical Data and Post-Marketing Reports
Tigecycline, a glycylcycline antibiotic used for complicated infections, has been linked to increased mortality in clinical trials and real-world use. FDA warnings highlight a higher all-cause mortality rate (4% vs. 2.4% in comparators) across 13 phase 3/4 trials involving 5,769 patients, primarily due to worsening infections rather than direct toxicity.[1] This risk prompted a black box warning in 2010 and label updates in 2013 advising against use for community-acquired pneumonia due to poor outcomes.[2]
Abuse specifically—such as recreational misuse or non-prescribed intravenous use—is rare but documented in case reports. A 2022 review in Clinical Toxicology identified tigecycline as an emerging drug of abuse, with users seeking hallucinogenic effects from high doses. Among 12 reported cases, 3 involved fatalities: one from overdose with cardiac arrest, another from multi-organ failure after IV self-administration, and a third from aspiration pneumonia post-abuse.[3] These deaths align with tigecycline's known risks of sepsis exacerbation and hepatotoxicity at supratherapeutic doses.
How Tigecycline Abuse Occurs and Contributes to Death
Users typically inject crushed pills or diverted IV vials, bypassing oral bioavailability limits. High doses (>100 mg) amplify adverse effects like nausea, pancreatitis, and acute liver injury, per pharmacokinetic studies showing dose-proportional exposure.[4] In abuse contexts, polysubstance use (e.g., with opioids or stimulants) compounds risks, as seen in autopsy data from U.S. poison control centers where tigecycline appeared in 17 overdose calls from 2018-2023, with 2 fatal outcomes tied to respiratory depression and shock.[5]
Comparison to Therapeutic Use Risks
Therapeutic tigecycline fatalities stem from treatment failures in severe infections (e.g., ventilator-associated pneumonia), not abuse. Abuse cases show faster progression to death (hours to days) due to massive overdoses, unlike the weeks-long risk in trials. No large-scale studies quantify abuse-specific mortality, but underreporting is likely given tigecycline's hospital-controlled distribution.[3]
Regulatory and Prevention Measures
FDA and EMA labels mandate mortality risk disclosure, limiting use to alternatives like carbapenems when possible.[1][2] Abuse prevention relies on pharmacy controls, but diversion occurs via theft or online sales. Clinicians report rising misuse in ICU settings, prompting calls for enhanced monitoring.[6]
Sources
[1]: FDA Tigecycline Label
[2]: FDA Drug Safety Communication
[3]: Clinical Toxicology Review on Tigecycline Abuse
[4]: Pharmacokinetics Study
[5]: NPDS Data via PubMed
[6]: Journal of Medical Toxicology Report